Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thrombolysis in Ischemic Spinal Cord Stroke
NCT02242084Phase 2Terminated
- Sponsor
- Rabin Medical Center
- Start
- Apr 2016
- Primary completion
- Mar 2019
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tissue-plasminogen activator in spinal cord infarction (SCInf), sponsored by Rabin Medical Center. Primary endpoint: Modified Ranking Scale at 3 months. Started Apr 2016; status: terminated.
02
Drugs
tissue-plasminogen activator
03
Conditions
spinal cord infarction (SCInf)
Beyond the preview
Go deeper on NCT02242084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02242084.